Gene therapy may help reverse blindness – The Tribune
The Tribune |
Gene therapy may help reverse blindness
The Tribune Researchers have shown that gene therapy might help reverse blindness by reprogramming cells at the back of the eye to become light sensitive. Retinitis pigmentosa — the most common cause of blindness in young people — occurs mostly due to loss of … Oxford study says blindness could be restored using gene therapyIndia Today Gene therapy may help reverse blindness: studyBusiness Standard |
Futurism |
Scientists Establish New Nonviral Method for CRISPR Using Gold …
Futurism CRISPR’s method of delivery has been raised as one limitation of the otherwise revolutionary technology. Now, a team of scientists has successfully tested a … CRISPR-Gold fixes Duchenne muscular dystrophy mutation in mice …UC Berkeley Gold nanoparticle used to replace virus in new CRISPR approachPhys.Org CRISPR/Cas9 Disrupts Glaucoma Gene, Takes Pressure off Eyes in Disease ModelsGenetic Engineering & Biotechnology News (blog) New University all 6 news articles » |
UC Berkeley |
CRISPR-Gold fixes Duchenne muscular dystrophy mutation in mice
UC Berkeley Scientists at the University of California, Berkeley, have engineered a new way to deliver CRISPR-Cas9 gene-editing technology inside cells and have demonstrated in mice that the technology can repair the mutation that causes Duchenne muscular … Scientists Establish New Nonviral Method for CRISPR Using Gold NanoparticlesFuturism CRISPR/Cas9 Disrupts Glaucoma Gene, Takes Pressure off Eyes in Disease ModelsGenetic Engineering & Biotechnology News (blog) Gold nanoparticle used to replace virus in new CRISPR approachPhys.Org |
Boston Business Journal |
After bidding war, Cambridge gene therapy firm Dimension accepts $151M buyout
Boston Business Journal After weighing buyout offers from two out-of-state biotechs, Cambridge gene therapy firm Dimension Therapeutics said Tuesday that it has accepted the superior proposal — a $151 million deal that will allow the company to maintain a local presence. Shoving Regenxbio aside, Ultragenyx’s Emil Kakkis closes Dimension buyout deal with 400% premiumEndpoints News In RARE news, Dimension dumps Regenxbio for better offerBioPharma Dive Ultragenyx to Acquire Dimension TherapeuticsP&T Community |
|
UK’s Cell and Gene Therapy Catapult Partners with Japan
BioPharm International The Cell and Gene Therapy Catapult (CGT Catapult), a UK center of excellence for building up the cell and gene therapy sector in the UK, announced on Oct. 3, 2017 that it has signed a Memorandum of Understanding (MoU) with Japan’s Forum for Innovative … |
|
Celsion’s DNA immunotherapy candidate GEN-1 shows continued positive effect in early-stage ovarian cancer study …
Seeking Alpha Thinly traded nano cap Celsion (CLSN +129.8%) is up on a whopping 36x surge in volume in response to its announcement of final results from a Phase 1b dose-escalating study of DNA immunotherapy GEN-1 in patients with advanced Stage III/IV ovarian … Celsion Announces Final Clinical and Translational Research Data from its OVATION Study at the AACR Special …Markets Insider Celsion Corporation (NASDAQ:CLSN) Stock Traded Higher Than Its 50 Day Moving AverageFirst News 24 |